United States Approves Moderna’s First Messenger RNA Influenza Vaccine
The United States Food and Drug Administration has approved a new seasonal influenza vaccine developed by Moderna using messenger RNA technology, marking a milestone in expanding the platform beyond its established use against other respiratory viruses.